Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is essential for contemporary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI). The gene discussed is P2RY12; the disease is myocardial infarction.